BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31102069)

  • 1. Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Lee SJ
    Endocrine; 2019 Jul; 65(1):110-120. PubMed ID: 31102069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Endocrinol Invest; 2018 Jun; 41(6):677-689. PubMed ID: 29147952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evodiamine Suppresses Survival, Proliferation, Migration and Epithelial-Mesenchymal Transition of Thyroid Carcinoma Cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Lee SJ
    Anticancer Res; 2018 Nov; 38(11):6339-6352. PubMed ID: 30396956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Tumour Biol; 2017 Oct; 39(10):1010428317722068. PubMed ID: 28982310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
    Lin SF; Lin JD; Chou TC; Huang YY; Wong RJ
    PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2018 Feb; 59(2):383-394. PubMed ID: 29285650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Tumour Biol; 2017 Feb; 39(2):1010428317692252. PubMed ID: 28218042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
    Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
    Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
    Yoshioka T; Yogosawa S; Yamada T; Kitawaki J; Sakai T
    Gynecol Oncol; 2013 May; 129(2):425-32. PubMed ID: 23403163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic effect of celastrol alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Tumour Biol; 2017 May; 39(5):1010428317698369. PubMed ID: 28459364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Biomed Pharmacother; 2016 Oct; 83():22-32. PubMed ID: 27470546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
    Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
    Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
    Zhang QC; Jiang SJ; Zhang S; Ma XB
    Asian Pac J Cancer Prev; 2012; 13(7):3471-6. PubMed ID: 22994780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
    Borbone E; Berlingieri MT; De Bellis F; Nebbioso A; Chiappetta G; Mai A; Altucci L; Fusco A
    Oncogene; 2010 Jan; 29(1):105-16. PubMed ID: 19802013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
    Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
    Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
    Spartalis E; Athanasiadis DI; Chrysikos D; Spartalis M; Boutzios G; Schizas D; Garmpis N; Damaskos C; Paschou SA; Ioannidis A; Tsourouflis G; Dimitroulis D; Nikiteas NI
    Anticancer Res; 2019 Mar; 39(3):1119-1127. PubMed ID: 30842140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.
    Dong X; Korch C; Meinkoth JL
    Endocr Relat Cancer; 2011 Jun; 18(3):301-10. PubMed ID: 21367844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.